Trichomoniasis: What's new?

Current Infectious Disease Reports

Volumn 5, Issue 2, 2003, Pages 129-134

  Wendel, Karen A ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FURAZOLIDONE; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; NONOXINOL 9; ORNIDAZOLE; PAROMOMYCIN; PLACEBO; TINIDAZOLE; VIRULENCE FACTOR;

CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INFECTION CONTROL; NONHUMAN; PAPANICOLAOU TEST; PERINATAL MORBIDITY; POLYMERASE CHAIN REACTION; PREVALENCE; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; VULVA DISEASE;

EID: 3142547350     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-003-0049-z     Document Type: Review

References (55)

1. World Health Organization: An Overview of Selected Curable Sexually Transmitted Diseases. Global Programme on AIDS Report. Geneva: World Health Organization; 1995.
2. Provenzano D, Alderete JF: Analysis of human immunoglobulin-degrading cysteine proteinases of Trichomonas vaginalis. Infect Immun 1995, 63:3388-3395.
3. Alderete JF: Iron modulates phenotypic variation and phosphorylation of P270 in double-stranded RNA virus-infected Trichomonas vaginalis. Infect Immun 1999, 67:4298-4302.
4. Peterson KM, Alderete JF: Host plasma proteins on the surface of pathogenic Trichomonas vaginalis. Infect Immun 1982, 37:755-762.
5. Arroyo R, Alderete JF: Two Trichomonas vaginalis surface proteinases bind to host epithelial cells and are related to levels of cytoadherence and cytotoxicity. Arch Med Res 1995, 26:279-285.
6. Crouch ML, Benchimol M, Alderete JF: Binding of fibronectin by Trichomonas vaginalis is influenced by iron and calcium. Microb Pathog 2001, 31:131-144.
7. Ryu JS, Choi HK, Min DY, et al.: Effect of iron on the virulence of Trichomonas vaginalis. J Parasitol 2001, 87:457-460.
8. Provenzano D, Khoshnan A, Alderete JF: Involvement of dsRNA virus in the protein composition and growth kinetics of host Trichomonas vaginalis. Arch Virol 1997, 142:939-952.
9. Wendel KA, Rompalo AM, Erbelding EJ, et al.: Double-stranded RNA viral infection of Trichomonas vaginalis infecting patients attending a sexually transmitted diseases clinic. J Infect Dis 2002, 186:558-561.
10. Paintlia MK, Kaur S, Gupta I, et al.: Specific IgA response, T-cell subtype and cytokine profile in experimental intravaginal trichomoniasis. Parasitol Res 2002, 88:338-343.
11. Buve A, Weiss HA, Laga M, et al.: The epidemiology of trichomoniasis in women in four African cities. AIDS 2001, 15(Suppl 4):S89-S96.
12. Madico G, Quinn TC, Rompalo A, et al.: Diagnosis of Trichomonas vaginalis infection by PCR using vaginal swab samples. J Clin Microbiol 1998, 36:3205-3210.
13. Cu-Uvin S, Hogan JW, Warren D, et al.: Prevalence of lower genital tract infections among human immunodeficiency virus HIV-seropositive and high-risk HIV-seronegative women. HIV Epidemiology Research Study Group. Clin Infect Dis 1999, 29:1145-1150.
14. Lawing LF, Hedges SR, Schwebke JR: Detection of trichomonosis in vaginal and urine specimens from women by culture and PCR. J Clin Microbiol 2000, 38:3585-3588.
15. Dragsted DM, Farholt S, Lind I: Occurrence of trichomoniasis in women in Denmark, 1967-1997. Sex Transm Dis 2001, 28:326-329.
16. Zhang ZF: Epidemiology of trichomonas vaginalis. A prospective study in China. Sex Transm Dis 1996, 23:415-424.
17. Sorvillo F, Kovacs A, Kerndt P, et al.: Risk factors for trichomoniasis among women with human immunodeficiency virus HIV infection at a public clinic in Los Angeles County, California: implications for HIV prevention. Am J Trop Med Hyg 1998, 58:495-500.
18. Wendel KA, Erbelding EJ, Gaydos CA, Rompalo AM: Trichomonas vaginalis polymerase chain reaction compared with standard diagnostic and therapeutic protocols for detection and treatment of vaginal trichomoniasis. Clin Infect Dis 2002, 35:576-580.
19. Joyner JL, Douglas JM Jr, Ragsdale S, et al.: Comparative prevalence of infection with Trichomonas vaginalis among men attending a sexually transmitted diseases clinic. Sex Transm Dis 2000, 27:236-240.
20. Krieger JN, Verdon M, Siegel N, et al.: Risk assessment and laboratory diagnosis of trichomoniasis in men. J Infect Dis 1992, 166:1362-1366.
21. Pepin J, Sobela F, Deslandes S, et al.: Etiology of urethral discharge in West Africa: the role of Mycoplasma genitalium and Trichomonas vaginalis. Bull WHO 2001, 79:118-126.
22. Morency P, Dubois MJ, Gresenguet G, et al.: Aetiology of urethral discharge in Bangui, Central African Republic. Sex Transm Infect 2001, 77:125-129.
23. Krieger JN, Verdon M, Siegel N, Holmes KK: Natural history of urogenital trichomoniasis in men. J Urol 1993, 149:1455-1458.
24. Cotch MF, Pastorek JG, Nugent RP, et al.: Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis 1997, 24:353-360.
25. Minkoff H, Grunebaum AN, Schwarz RH, et al.: Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. Am J Obstet Gynecol 1984, 150:965-972.
26. Moodley P, Wilkinson D, Connolly C, et al.: Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis 2002, 34:519-522.
27. Laga M, Manoka A, Kivuvu M, et al.: Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993, 7:95-102.
28. Wang CC, McClelland RS, Reilly M, et al.: The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 2001, 183:1017-1022.
29. Klebanoff MA, Carey JC, Hauth JC, et al.: Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001, 345:487-493.
30. Paisarntantiwong R, Brockmann S, Clarke L, et al.: The relationship of vaginal trichomoniasis and pelvic inflammatory disease among women colonized with Chlamydia trachomatis. Sex Transm Dis 1995, 22:344-347.
31. Chuachoowong R, Shaffer N, Siriwasin W, et al.: Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis 2000, 181:99-106.
32. Catterall RD, Nicol CS: Is trichomonal infestation a venereal disease? BMJ 1960, 1:1177-1179.
33. Weston TE, Nicol CS: Natural history of trichomonal infection in males. Br J Venereal Dis 1963, 39:251-257.
34. Kuberski T: Trichomonas vaginalis associated with nongonococcal urethritis and prostatitis. Sex Transm Dis 1980, 7:135-136.
35. Skerk V, Schonwald S, Krhen I, et al.: Aetiology of chronic prostatitis. Int J Antimicrob Agents 2002, 19:471-474.
36. Hobbs MM, Kazembe P, Reed AW, et al.: Trichomonas vaginalis as a cause of urethritis in Malawian men. Sex Transm Dis 1999, 26:381-387.
37. Wiese W, Patel SR, Patel SC, et al.: A meta-analysis of the Papanicolaou smear and wet mount for the diagnosis of vaginal trichomoniasis. Am J Med 2000, 108:301-308.
38. Patel SR, Wiese W, Patel SC, et al.: Systematic review of diagnostic tests for vaginal trichomoniasis. Infect Dis Obstet Gynecol 2000, 8:248-257.
39. Kaydos SC, Swygard H, Wise SL, et al.: Development and validation of a PCR-based enzyme-linked immunosorbent assay with urine for use in clinical research settings to detect Trichomonas vaginalis in women. J Clin Microbiol 2002, 40:89-95.
40. Mayta H, Gilman RH, Calderon MM, et al.: 18S ribosomal DNA-based PCR for diagnosis of Trichomonas vaginalis. J Clin Microbiol 2000, 38:2683-2687.
41. Lawing LF, Hedges SR, Schwebke JR: Detection of trichomonosis in vaginal and urine specimens from women by culture and PCR. J Clin Microbiol 2000, 38:3585-3588.
42. Saxena SB, Jenkins RR: Prevalence of Trichomonas vaginalis in men at high risk for sexually transmitted diseases. Sex Transm Dis 1991, 18:138-142.
43. Borchardt KA, al Haraci S, Maida N: Prevalence of Trichomonas vaginalis in a male sexually transmitted disease clinic population by interview, wet mount microscopy, and the InPouch TV test. Genitourin Med 1995, 71:405-406.
44. Schwebke JR, Lawing LF: Improved Detection by DNA Amplification of Trichomonas vaginalis in Males. J Clin Microbiol 2002, 40:3681-3683.
45. Centers for Disease Control and Prevention: Sexually transmitted diseases treatment guidelines 2002. MMWR 2002, 51RR-6:1-78.
46. Upcroft F, Upcroft JA: Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev 2001, 14:150-164.
47. Land KM, Clemens DL, Johnson PJ: Loss of multiple hydrogenosomal proteins associated with organelle metabolism and high-level drug resistance in trichomonads. Exp Parasitol 2001, 97:102-110.
48. Schmid G, Narcisi E, Mosure D, et al.: Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med 2001, 46:545-549.
49. Perez S, Fernandez-Verdugo A, Perez F, Vazquez F: Prevalence of 5-nitroimidazole-resistant trichomonas vaginalis in Oviedo, Spain. Sex Transm Dis 2001, 28:115-116.
50. Muller M, Lossick JG, Gorrell TE: In vitro susceptibility of Trichomonas vaginalis to metronidazole and treatment outcome in vaginal trichomoniasis. Sex Transm Dis 1988, 15:17-24.
51. Rasoloson D, Vanacova S, Tomkova E, et al.: Mechanisms of in vitro development of resistance to metronidazole in Trichomonas vaginalis. Microbiology 2002, 148(Pt 8):2467-2477.
52. Rasoloson D, Tomkova E, Cammack R, et al.: Metronidazole-resistant strains of Trichomonas vaginalis display increased susceptibility to oxygen. Parasitology 2001, 123(Pt 1):45-56.
53. Lossick JG, Muller M, Gorrell TE: In vitro drug susceptibility and doses of metronidazole required for cure in cases of refractory vaginal trichomoniasis. J Infect Dis 1986, 153:948-955.
54. Sobel JD, Nyirjesy P, Brown W: Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis 2001, 33:1341-1346.
55. Saurina G, DeMeo L, McCormack WM: Cure of metronidazole- and tinidazole-resistant trichomoniasis with use of high-dose oral and intravaginal tinidazole. Clin Infect Dis 1998, 26:1238-1239.